BRAF and melanoma: Notably, OTX-008 cooperated with EG00229 to achieve resensitization to therapy of BRAF-inhibitor-resistant melanoma cells (Figure 5A,B, yellow bars in left graphs), comparable to the responses observed in parental drug-sensitive cells (check Figure S1C).